← Back to Search

Albumin group for Liver Transplant

N/A
Waitlist Available
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative
Awards & highlights

Study Summary

The purpose of the study is to examine if outcome after liver transplantation is improved by using albumin infusion post-transplantation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-op day 7, 15, 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-op day 7, 15, 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Liver Function Tests
Secondary outcome measures
Calculated creatinine clearance
Functional 6 minutes walking test
Functional hand grip Jamar Dynamometer hand grip test
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Albumin groupExperimental Treatment1 Intervention
Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
Group II: Control GroupActive Control1 Intervention
Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
442 Previous Clinical Trials
159,074 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Apr 2025